S14 Implants France

S14 Implants  Consisted of a highly skilled and creative team of surgeons and engineers, S14 Implants brings its expertise in spinal implants and biocompatible polymers to design and manufacture a new generation of products with superior outcomes. Industry sectors Medtech Therapeutics Area Orthopedics/Orthopedic Surgery
Your innovative solution

Our unique technology combines visco elastic shock absorbers with rigid components in one device to restore the anatomical functions. Our first product 

Which problem are you solving ?

B Dyn relieves pressure on the inter vertebral disc as well as the articular facets and by controlling motion, preserves the intervertebral disc and the articular facets from final fusion. For the patients the outcomes evaluated 2 years after the surgery are superior to the standard technic of fusion.

Target market segments

Lumbar Spine Degenerative Market

Key value proposition

Superior clinical outcomes 


Sanofi United States


engaged in the research, development, manufacturing and marketing of therapeutic solutions focused on patients’ needs. Sanofi has core strengths in diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and Genzyme.

Miss Aurelie Charpentier
R&D Transactions Contract Manager 
Mr Kenneth Bennett
Sr. Director - US Diabetes 
Mrs Pia D'Urbano


Our software enables a rapid development of web or mobile portals or "app stores", dedicated to help people to manage their health or autonomy.

Technically, we facilitate interaction between services, serious games, algorithms and medical contents that will be integrated in a single portal where they will have a single management tool and one single database.

In addition, an administration tool enables to its operator the management of the platform : CMS, enrollment, statistics and connectors.

To date, we expect 1 M€ turnover in 2015, with 6 customers, mainly insurers and state organization like CNAM, the equivalent of NHS, the Regional Health Agency (ARS Ile de France) or City of Paris.

For instance, we have developed an e-health portal for employees. This portal, called "MyPrevention", integrates 12 inter-connected applications : e-health prevention applications, an encyclopedia, information and coaching platforms, ...

The services are provided by 12 different companies.

About this project, our lauching plan, forecasts 50 000 users by the end of October 2015 and 400.000 in 2016.

We have also developped a social network which integrates a serious game, an agenda, a visio conference access, a connection with a services platform.

This project has been designed for the dependant persons of the city of Paris and will be launched and operated by the Welfare Department of the City of Paris.

Even if the French market is still under creation, we strongly believe that market shares must be grabbed now. So far, we have a successful commercial activity and we are strongly confident that we will be in a strong position to address a mass e-health market. 

This market will be driven by the demand expressed by end users who expect more collaboration between insurers, national healthcare operators , pharmaceutical labs,  in order to provide them with integrated care services.

Our strategy is always the same :

- identifying the main actors on a market

- finalizing partnership in order to adress the market behind his brand and his expertise.

Mr Christophe Lorieux


Our Mission is to discover and develop better therapeutic options
      for patients suffering from unmanageable diseases

We understand that diseases are complex, treatments are unsatisfactory, and drug development processes are long, expensive and inefficient.  Our approach to pharmaceutical research and development is driven by a deeper understanding of diseases at the biological systems level and designing therapeutic strategies to solve specific patient problems.

We are committed to maximizing resource utilization and making conscious efforts to undertake projects ranging from low risk to high risk -- including (1) developing newer formulations of existing drugs, (2) repurposing older drugs, (3) developing new drugs against precedented targets, and (4) discovering drug-candidates against unprecedented targets, with increasing risk profiles in that order.

Our goals are to:

  • Improve existing drugs using our proprietary formulation technology
  • Explore world-wide markets for product launches
  • Develop strategic partnerships for developed products
  • Develop alliances with multinational pharmaceutical companies
  • Increase value for patients and investors

At Sarfez we are committed to discover successful treatments for diseases and passionate about making a difference in the lives of patients.

Dr Salim Shah

SBH Sciences United States

Dr Raphael Nir

Schiff Hardin LLP United States

Mr Philippe C.M. Manteau

Secuderm France

Mr Eric Gilli

Selenium Medical France

Selenium Medical Selenium Medical is an innovative solutions provider and contract manufacturing partner expert in surface treatment, medical packaging and new innovative solutions development. Industry sectors Medtech Therapeutics Area Dental and Oral Health
Orthopedics/Orthopedic Surgery
Your innovative solution

SoTube/SoSafe are two innovative medical packaging solutions, nested tubes based, for implants double-sterile barrier packaging. Compared to double-pouches/double-blisters, these double-tubes ensure nurses and surgeons easy handling of package and implant as well as a pioneer 100% No Touch approach right up to the point of surgery.

Which problem are you solving ?

Their benefits over traditional packages: 10 times smaller and lighter than traditional packages, more eco-friendly, "NoTouch" approach capability reducing aseptic faults in the operating room, 5 years shelf life and sterility guaranteed, fast opening, secured manipulation, storage optimization, reduce operating time, easy to implement, economy & marketing edge, etc.

Target market segments

Orthopedic / Foot and hands / Spine /

Key value proposition

1: Patented products and its no touch application / 2: CE marked and FDA approved / 3: storage optimization / 4: easier identification and manipulation

Mr Olivier RICHART

Semma Therapeutics United States

Type 1 diabetes (T1D), formerly known as juvenile diabetes, is a chronic, life-threatening disease that affects millions of people worldwide. In the United States, 30,000 new cases are estimated every year with half of those cases diagnosed in young children. Type 1 diabetes is an autoimmune disease in which the patient’s immune system goes awry and attacks and destroys the pancreatic beta cells. Beta cells are responsible for regulating blood sugar (glucose) levels by producing precise amounts of the essential hormone insulin.

The discovery of injectable insulin in the 1920s changed T1D from a uniformly fatal disease with a life expectancy of months to one that could be carefully managed for decades through multiple daily blood glucose measurements and insulin injections. However, insulin injections are not a cure and patients face a lifetime of difficult disease management and serious complications including kidney failure, blindness and nerve damage. Despite nearly a century passing since the discovery of insulin, insulin injection remains the only treatment available to patients.

Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. Recent work in the laboratory of Professor Douglas Melton led to the discovery of a method to generate billions of functional, insulin-producing beta cells in the laboratory. These cells develop in islet-like clusters grown from stem cells. Initial preclinical work in animal models of diabetes has shown that transplantation of these cells are sufficient to control blood glucose levels. This breakthrough technology has been exclusively licensed to Semma Therapeutics for the development of a cell-based therapy for diabetes.

Ongoing research at Semma Therapeutics is focused on combining these proprietary cells with a state-of-the-art cell delivery and immune protection strategy that can protect these cells from the patient’s immune system and allow the beta cells to function as they do in non-diabetic individuals. Implantation of the beta cell-filled device has the potential to provide a true replacement for the missing beta cells in a diabetic patient and would not require patient immunosuppression. Semma Therapeutics is working to bring this new therapeutic option to the clinic and improve the lives of patients with diabetes.

Dr Felicia Pagliuca
Director of Technology and Corporate Development 

Seneca Diabetes Foundation United States

Ms Holly John
Member-Board of Directors